PL3411076T3 - Koniugaty przeciwciało-lek ukierunkowane na uparap - Google Patents

Koniugaty przeciwciało-lek ukierunkowane na uparap

Info

Publication number
PL3411076T3
PL3411076T3 PL17706673T PL17706673T PL3411076T3 PL 3411076 T3 PL3411076 T3 PL 3411076T3 PL 17706673 T PL17706673 T PL 17706673T PL 17706673 T PL17706673 T PL 17706673T PL 3411076 T3 PL3411076 T3 PL 3411076T3
Authority
PL
Poland
Prior art keywords
uparap
drug conjugates
targeted antibody
antibody
targeted
Prior art date
Application number
PL17706673T
Other languages
English (en)
Inventor
Christoffer NIELSEN
Niels Behrendt
Lars Henning ENGELHOLM
Original Assignee
Rigshospitalet
University Of Copenhagen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet, University Of Copenhagen filed Critical Rigshospitalet
Publication of PL3411076T3 publication Critical patent/PL3411076T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
PL17706673T 2016-02-05 2017-02-03 Koniugaty przeciwciało-lek ukierunkowane na uparap PL3411076T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201670063 2016-02-05
DKPA201670834 2016-10-24
PCT/DK2017/050024 WO2017133745A1 (en) 2016-02-05 2017-02-03 ANTIBODY-DRUG CONJUGATES TARGETING uPARAP
EP17706673.5A EP3411076B1 (en) 2016-02-05 2017-02-03 Antibody-drug conjugates targeting uparap

Publications (1)

Publication Number Publication Date
PL3411076T3 true PL3411076T3 (pl) 2021-11-02

Family

ID=58108381

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17706673T PL3411076T3 (pl) 2016-02-05 2017-02-03 Koniugaty przeciwciało-lek ukierunkowane na uparap
PL21170407.7T PL3895736T3 (pl) 2016-02-05 2017-02-03 Koniugaty przeciwciało-lek ukierunkowane na uparap

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21170407.7T PL3895736T3 (pl) 2016-02-05 2017-02-03 Koniugaty przeciwciało-lek ukierunkowane na uparap

Country Status (23)

Country Link
US (3) US10940213B2 (pl)
EP (2) EP3411076B1 (pl)
JP (2) JP7125059B2 (pl)
KR (2) KR20260021643A (pl)
CN (1) CN108883197B (pl)
AU (1) AU2017215869B2 (pl)
BR (1) BR112018015448A2 (pl)
CA (1) CA3013677C (pl)
CY (2) CY1124280T1 (pl)
DK (2) DK3895736T5 (pl)
ES (2) ES2874668T3 (pl)
FI (1) FI3895736T3 (pl)
HR (2) HRP20230505T1 (pl)
HU (2) HUE054938T2 (pl)
LT (2) LT3411076T (pl)
MX (2) MX2018009461A (pl)
PL (2) PL3411076T3 (pl)
PT (2) PT3895736T (pl)
RS (2) RS62115B1 (pl)
RU (1) RU2740311C2 (pl)
SI (2) SI3895736T1 (pl)
SM (1) SMT202100386T1 (pl)
WO (1) WO2017133745A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260021643A (ko) 2016-02-05 2026-02-13 릭스하스피탈렛 uPARAP을 표적으로 하는 항체-약물 접합체
EP4363447A1 (en) 2021-06-29 2024-05-08 Rigshospitalet Antibody-drug conjugates comprising humanized antibodies targeting urokinase type plasminogen activator receptor associated protein (uparap)
TW202434231A (zh) 2022-12-28 2024-09-01 丹麥商阿德森多私人有限公司 包含依喜替康衍生物之靶向uPARAP的抗體-藥物結合物
WO2025099152A1 (en) * 2023-11-08 2025-05-15 Rigshospitalet Antibodies and molecular conjugates thereof targeting upar
WO2025141153A1 (en) 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates
EP4578463A1 (en) * 2023-12-29 2025-07-02 Oncomatryx Biopharma, S.L. Endo-180 targeted antibody-drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
JP2004137151A (ja) 2002-10-15 2004-05-13 Keio Gijuku 脳腫瘍の治療・診断薬
US8444983B2 (en) 2009-03-23 2013-05-21 Quark Pharmaceuticals, Inc. Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
JP2015509085A (ja) 2012-01-01 2015-03-26 キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子
RU2530553C2 (ru) * 2012-11-07 2014-10-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Рекомбинантное однодоменное антитело, способное специфически связывать фактор некроза опухолей человека, и его производные
KR20260021643A (ko) 2016-02-05 2026-02-13 릭스하스피탈렛 uPARAP을 표적으로 하는 항체-약물 접합체

Also Published As

Publication number Publication date
RS62115B1 (sr) 2021-08-31
CN108883197B (zh) 2022-05-10
JP2019511205A (ja) 2019-04-25
ES2874668T3 (es) 2021-11-05
RS64219B1 (sr) 2023-06-30
ES2946073T3 (es) 2023-07-12
HRP20230505T1 (hr) 2023-08-04
DK3895736T3 (da) 2023-07-24
HUE061880T2 (hu) 2023-08-28
JP7125059B2 (ja) 2022-08-24
CA3013677A1 (en) 2017-08-10
US20190046658A1 (en) 2019-02-14
EP3895736A1 (en) 2021-10-20
RU2018125309A (ru) 2020-03-06
SI3411076T1 (sl) 2021-09-30
AU2017215869B2 (en) 2024-02-01
HRP20211152T1 (hr) 2021-10-15
PL3895736T3 (pl) 2023-07-24
EP3411076A1 (en) 2018-12-12
SI3895736T1 (sl) 2023-07-31
US20240131179A1 (en) 2024-04-25
PT3895736T (pt) 2023-06-02
HK1258338A1 (en) 2019-11-08
DK3411076T3 (da) 2021-07-26
KR20260021643A (ko) 2026-02-13
LT3895736T (lt) 2023-06-12
CY1126032T1 (el) 2023-11-15
CA3013677C (en) 2025-09-23
CN108883197A (zh) 2018-11-23
RU2018125309A3 (pl) 2020-04-27
WO2017133745A1 (en) 2017-08-10
US10940213B2 (en) 2021-03-09
EP3895736B1 (en) 2023-04-19
JP7304595B2 (ja) 2023-07-07
SMT202100386T1 (it) 2021-09-14
JP2022064906A (ja) 2022-04-26
LT3411076T (lt) 2021-07-26
HUE054938T2 (hu) 2021-10-28
US11819552B2 (en) 2023-11-21
BR112018015448A2 (en) 2018-12-18
US20240226317A9 (en) 2024-07-11
AU2017215869A1 (en) 2018-07-19
MX2018009461A (es) 2018-12-11
MX2022014231A (es) 2022-12-07
FI3895736T3 (fi) 2023-06-26
DK3895736T5 (da) 2024-06-10
PT3411076T (pt) 2021-06-17
KR20180105155A (ko) 2018-09-27
RU2740311C2 (ru) 2021-01-13
US20210162062A1 (en) 2021-06-03
EP3411076B1 (en) 2021-04-28
KR102904012B1 (ko) 2025-12-26
CY1124280T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
CY2021018I2 (el) Συζευγμα αντισωματος anti-her2-φαρμακου
LT3525830T (lt) Pirolbenzodiazepino konjugatai
MA50755A (fr) Conjugués anticorps-médicaments mult-médicaments
DK3579883T3 (da) Pyrrolobenzodiazepin-antistofkonjugater
PL3423105T3 (pl) Koniugaty przeciwciało-lek oparte na erybulinie i sposoby zastosowania
DK3592393T3 (da) Frigørbare konjugater
DK3137114T3 (da) Anti-PTK7-antistof-lægemiddelkonjugater
MA51778A (fr) Conjugués anticorps-médicament anti-ccr7
EP3313857A4 (en) POLYMER-CYCLODEXTRIN LIPID CONJUGATES
DK3268047T3 (da) Amatoxin/antistof-konjugater
LT3544636T (lt) Pirolobenzodiazepino-antikūno konjugatai
DK3423104T5 (da) Amanitin-konjugater
HUE049622T2 (hu) Magas drog-töltöttségû ellenanyag-drog konjugátumok
DK3297649T3 (da) Peptid-oligonukleotid-konjugater
IL241277A0 (en) Antibody drug conjugates
DK3119885T3 (da) Antistof-fynomer-konjugater
HUE049291T2 (hu) Antitest-hatóanyag konjugátumok és immuntoxinok
PT3003386T (pt) Conjugados anticorpo-fármaco
DK3668874T3 (da) Pyrrolobenzodiazepin-konjugater
DK3148591T3 (da) Nanopartikel-lægemiddelkonjugater
DK3612537T3 (da) Pyrrolobenzodiazepinkonjugater
PL3411076T3 (pl) Koniugaty przeciwciało-lek ukierunkowane na uparap
PT3478323T (pt) Conjugados de polímero-fármaco cliváveis
DK3684416T3 (da) Psma-målrettede amanitinkonjugater
DK3544634T3 (da) MET-antistof-lægemiddelkonjugater